NXTC – Nextcure Inc
NXTC
$5.75Name : NextCure, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $26,329,382.00
EPSttm : -8.71
NextCure, Inc.
$5.75
NXTC — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
5.77
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
1.05
EPS Last/This Y
13.31
EPS This/Next Y
0.45
Price
5.82
Target Price
20
Analyst Recom
1
Performance Q
-26.81
Upside
-6,298.2%
Beta
1.2
Ticker: NXTC
22 items
«
‹
of 1
›
»
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-10-12 | NXTC | 6.66 | N/A | N/A | 0 |
| 2026-10-13 | NXTC | 6.68 | N/A | N/A | 0 |
| 2026-10-14 | NXTC | 6.63 | N/A | N/A | 0 |
| 2026-10-15 | NXTC | 7.07 | N/A | N/A | 0 |
| 2026-10-16 | NXTC | 6.41 | N/A | N/A | 0 |
| 2026-10-19 | NXTC | 5.48 | N/A | N/A | 0 |
| 2026-10-20 | NXTC | 5.34 | N/A | N/A | 0 |
| 2026-10-21 | NXTC | 5.26 | N/A | N/A | 0 |
| 2026-10-22 | NXTC | 4.61 | N/A | N/A | 0 |
| 2026-10-23 | NXTC | 4.98 | N/A | N/A | 0 |
| 2026-10-26 | NXTC | 5.22 | N/A | N/A | 0 |
| 2026-10-27 | NXTC | 5.66 | N/A | N/A | 0 |
| 2026-10-28 | NXTC | 6.3 | N/A | N/A | 0 |
| 2026-10-29 | NXTC | 6.58 | N/A | N/A | 0 |
| 2026-10-30 | NXTC | 6.27 | N/A | N/A | 0 |
| 2026-11-02 | NXTC | 5.63 | N/A | N/A | 0 |
| 2026-11-03 | NXTC | 5.89 | N/A | N/A | 0 |
| 2026-11-04 | NXTC | 5.89 | N/A | N/A | 0 |
| 2026-11-05 | NXTC | 5.105 | N/A | N/A | 0 |
| 2026-11-06 | NXTC | 5.54 | N/A | N/A | 0 |
| 2026-11-09 | NXTC | 6.02 | N/A | N/A | 0 |
| 2026-11-10 | NXTC | 6.08 | N/A | N/A | 0 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
22 items
«
‹
Current Page1 of 1
›
»
22 items
«
‹
of 1
›
»
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-10-12 | NXTC | 6.90 | 72.1 | - | -6.34 |
| 2026-10-13 | NXTC | 6.36 | 72.1 | - | -6.34 |
| 2026-10-14 | NXTC | 6.63 | 72.1 | - | -6.34 |
| 2026-10-15 | NXTC | 6.99 | 72.1 | - | -6.34 |
| 2026-10-16 | NXTC | 6.32 | 72.1 | - | -6.34 |
| 2026-10-19 | NXTC | 5.51 | 72.1 | - | -6.34 |
| 2026-10-20 | NXTC | 5.51 | 72.1 | - | -6.34 |
| 2026-10-21 | NXTC | 5.49 | 72.1 | - | -6.34 |
| 2026-10-22 | NXTC | 4.73 | 72.1 | - | -6.34 |
| 2026-10-23 | NXTC | 4.95 | 72.1 | - | -6.34 |
| 2026-10-26 | NXTC | 5.24 | 72.1 | - | -6.34 |
| 2026-10-27 | NXTC | 5.64 | 72.1 | - | -6.34 |
| 2026-10-28 | NXTC | 6.23 | 72.1 | - | -6.34 |
| 2026-10-29 | NXTC | 6.63 | 72.1 | - | -6.34 |
| 2026-10-30 | NXTC | 6.30 | 72.1 | - | -6.34 |
| 2026-11-02 | NXTC | 5.70 | 72.1 | - | -6.34 |
| 2026-11-03 | NXTC | 5.81 | 72.1 | - | -6.34 |
| 2026-11-04 | NXTC | 5.87 | 72.1 | - | -6.34 |
| 2026-11-05 | NXTC | 5.15 | 72.1 | - | -6.34 |
| 2026-11-06 | NXTC | 5.69 | 72.1 | - | -6.34 |
| 2026-11-09 | NXTC | 6.02 | 72.1 | - | -6.34 |
| 2026-11-10 | NXTC | 5.82 | 72.1 | - | -6.34 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
22 items
«
‹
Current Page1 of 1
›
»
21 items
«
‹
of 1
›
»
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-10-12 | NXTC | 73.76 | -14.74 | 5.57 |
| 2026-10-13 | NXTC | 73.76 | -14.74 | 5.57 |
| 2026-10-14 | NXTC | 73.79 | -14.74 | 5.57 |
| 2026-10-15 | NXTC | 73.76 | -14.74 | 5.57 |
| 2026-10-16 | NXTC | 73.77 | -14.74 | 5.57 |
| 2026-10-19 | NXTC | 73.70 | -14.74 | 5.57 |
| 2026-10-20 | NXTC | 73.70 | -14.74 | 5.57 |
| 2026-10-21 | NXTC | 73.80 | -14.74 | 5.57 |
| 2026-10-22 | NXTC | 73.78 | -14.74 | 5.57 |
| 2026-10-23 | NXTC | 73.76 | -14.74 | 5.57 |
| 2026-10-26 | NXTC | 73.70 | -14.74 | 5.57 |
| 2026-10-27 | NXTC | 73.76 | -14.74 | 5.77 |
| 2026-10-28 | NXTC | 78.26 | -14.74 | 5.77 |
| 2026-10-29 | NXTC | 78.28 | -14.74 | 5.77 |
| 2026-10-30 | NXTC | 78.29 | -14.74 | 5.77 |
| 2026-11-02 | NXTC | 78.30 | -6.43 | 5.77 |
| 2026-11-03 | NXTC | 78.30 | -6.43 | 5.77 |
| 2026-11-05 | NXTC | 78.29 | -6.43 | 5.77 |
| 2026-11-06 | NXTC | 78.27 | -6.43 | 5.77 |
| 2026-11-09 | NXTC | 78.27 | -6.42 | 5.77 |
| 2026-11-10 | NXTC | 80.29 | -6.42 | 5.77 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
21 items
«
‹
Current Page1 of 1
›
»
Last Quarter Act. EPS
-1.84
Avg. EPS Est. Current Quarter
-0.9
Avg. EPS Est. Next Quarter
-0.79
Insider Transactions
80.29
Institutional Transactions
-6.42
Beta
1.2
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
5
Growth Score
19
Sentiment Score
85
Actual DrawDown %
92.8
Max Drawdown 5-Year %
-98
Target Price
20
P/E
Forward P/E
PEG
P/S
P/B
2
P/Free Cash Flow
EPS
-10.59
Average EPS Est. Cur. Y
-6.34
EPS Next Y. (Est.)
-5.89
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
0.66
Return on Equity vs Sector %
-100
Return on Equity vs Industry %
-100
EPS 1 7Days Diff
-0.1
EPS 1 30Days Diff
1.12
EBIT Estimation
◆
NXTC
Healthcare
$5.98
📉
N/A
Swing / Pullback
Buy the dip on strong trends
WEAK
Trend
6/20
Pullback
11/25
Volume
9/15
Valuation
12/20
TP/AR
2/10
Options
0/10
RSI
51.3
Range 1M
52.2%
Sup Dist
6.4%
🚀
N/A
Momentum Growth
Ride accelerating trends
WEAK
Momentum
4/25
Growth
23/30
Estimates
0/20
Inst/Vol
0/15
Options
0/10
EPS Yr
67.7%
EPS NY
78.2%
52W%
32%
💎
N/A
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+234.4% upside
Quality
2/30
Valuation
16/30
Growth
17/25
Stability
5/10
LT Trend
1/5
Upside
+234.4%
Quality
5
Click a card to see score breakdown
Full Analysis →
NXTC — P/E HistoricalBiotechnology
Sector: Healthcare
Industry: Biotechnology
Employees: 40
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. The company was incorporated in 2015 and is headquartered in Baltimore, Maryland.
NXTC
Latest News
—
Caricamento notizie per NXTC…
stock quote shares NXTC – Nextcure Inc Stock Price stock today
news today NXTC – Nextcure Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch NXTC – Nextcure Inc yahoo finance google finance
stock history NXTC – Nextcure Inc invest stock market
stock prices NXTC premarket after hours
ticker NXTC fair value insiders trading